Literature DB >> 17148031

Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation.

L Ruggeri1, A Mancusi, E Burchielli, F Aversa, M F Martelli, A Velardi.   

Abstract

In haplo-identical hematopoietic transplantation, donor vs. recipient natural killer (NK) cell alloreactivity derives from a mismatch between donor NK clones bearing inhibitory killer cell Ig-like receptors (KIR) for self-HLA class I molecules and their HLA class I ligands (KIR ligands) on recipient cells. When faced with mismatched allogeneic targets, these NK clones sense the missing expression of self-HLA class I alleles and mediate alloreactions. KIR ligand mismatches in the GvH direction trigger donor vs. recipient NK cell alloreactions, which improve engraftment, do not cause GvHD and control relapse in AML patients . The mechanism whereby alloreactive NK cells exert their benefits in transplantation has been elucidated in mouse models. The infusion of alloreactive NK cells ablates (i) leukemic cells, (ii) recipient T cells that reject the graft and (iii) recipient DC that trigger GvHD, thus protecting from GvHD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17148031     DOI: 10.1080/14653240601078721

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  16 in total

Review 1.  Immunotherapy prospects for acute myeloid leukaemia.

Authors:  A J Barrett; K Le Blanc
Journal:  Clin Exp Immunol       Date:  2010-05-31       Impact factor: 4.330

Review 2.  Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Jian-Ming Li; Cynthia R Giver; Ying Lu; Mohammad S Hossain; Mojtaba Akhtari; Edmund K Waller
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

3.  Efficacy of pretreatment of allografts with methoxypolyethylene glycol-succinimidyl-propionic acid ester in combination with an anti-OX40L monoclonal antibody in relieving graft-versus-host disease in mice.

Authors:  Yihong Huang; Saran Feng; Renxian Tang; Bing Du; Kailin Xu; Xiuying Pan
Journal:  Int J Hematol       Date:  2010-10-17       Impact factor: 2.490

Review 4.  Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer.

Authors:  Robert R Jenq; Marcel R M van den Brink
Journal:  Nat Rev Cancer       Date:  2010-02-19       Impact factor: 60.716

5.  Umbilical cord blood-derived mesenchymal stem cells ameliorate graft-versus-host disease following allogeneic hematopoietic stem cell transplantation through multiple immunoregulations.

Authors:  Qiu-Ling Wu; Xiao-Yun Liu; Di-Min Nie; Xia-Xia Zhu; Jun Fang; Yong You; Zhao-Dong Zhong; Ling-Hui Xia; Mei Hong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31

Review 6.  Prophylaxis of acute GVHD: manipulate the graft or the environment?

Authors:  A John Barrett; Katarina Le Blanc
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020

Review 7.  Natural Killer Cells for Therapy of Leukemia.

Authors:  Garnet Suck; Yeh Ching Linn; Torsten Tonn
Journal:  Transfus Med Hemother       Date:  2016-03-22       Impact factor: 3.747

8.  Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome.

Authors:  Richard W Childs; Xin Tian; Phuong Vo; Enkhtsetseg Purev; Ritesh R Kotecha; Mattias Carlsten; Joseph Clara; Willy A Flegel; Sharon D Adams; Hanh M Khuu; David F Stroncek; Lisa Cook; Tat'yana Worthy; Nancy L Geller; Brian Wells; Jennifer Wilder; Robert Reger; Georg Aue
Journal:  Br J Haematol       Date:  2021-05-15       Impact factor: 8.615

Review 9.  Graft-Versus-Solid-Tumor Effect: From Hematopoietic Stem Cell Transplantation to Adoptive Cell Therapies.

Authors:  Stefan Barisic; Richard W Childs
Journal:  Stem Cells       Date:  2022-06-22       Impact factor: 5.845

Review 10.  Understanding of molecular mechanisms in natural killer cell therapy.

Authors:  Suk Ran Yoon; Tae-Don Kim; Inpyo Choi
Journal:  Exp Mol Med       Date:  2015-02-13       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.